Following FDA approval of Imaavy, we explore promising biotech candidates in development for myasthenia gravis.

Real estate agent Kirsten Jordan breaks down the latest trends in the housing market, near-record home sale cancellations in April and her outlook on mortgage rates. Myasthenia gravis is a rare, ...

RemeGen Co., Ltd.(688331.SH / 09995.HK) announced that Telitacicept has officially been approved for marketing in China by the National Medical Products Administration (NMPA) for the treatment of ...

A new study will evaluate the safety and efficacy of universal allogeneic anti-CD19/BCMA CAR T-cells in relapsed or refractory autoimmune diseases including antineutrophil cytoplasmic antibody ...

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) ...

GlycoEra’s lead candidate targets IgG4 autoantibodies, potentially addressing autoimmune diseases such as muscle-specific ...

Winnacunnet High School senior Joe LaBrecque was diagnosed with myasthenia gravis, a rare neuromuscular autoimmune disorder. LaBrecque is raising awareness about the disease and participating in ...

Myasthenia gravis (MG) is a rare ... including the treatment of other autoimmune diseases driven by Th17-mediated inflammation. However, researchers caution that further work is needed to evaluate ...

ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and ...

According to Kevin Dutton, a British psychologist and author, and assorted studies, the 10 careers with the highest ...

The FDA has approved Johnson & Johnson's anti-FcRn antibody, nipocalimab, for the treatment of generalized myasthenia gravis. The drug will be sold under the brand name IMAAVY. This approval ...